The latest news from the global pharmaceutical industry. Below you will find news and information to keep you up-to-date with what is happening in your industry. Coverage includes regulatory approvals, recall announcements, mergers and acquisitions, personnel news and appointments, new facility and facility expansion updates, collaborations and agreements, and financial updates.
Friday, September 22, 2017
Allergan announced top-line results from new data for the CENTAUR Phase 2b study which supports the anti-fibrotic efficacy and safety of Cenicriviroc ...
read more
Thursday, September 21, 2017
In a recent study, researchers produced genetically engineered antibodies with the highest activity and breadth of coverage yet seen against HIV-1.
read more
Thursday, September 21, 2017
Audentes Therapeutics has commenced dosing of patients in ASPIRO, a Phase 1/2 clinical trial of AT132 for the treatment of X-Linked Myotubular ...
read more
Wednesday, September 20, 2017
The NIDCR has awarded Soligenix a SBIR grant over two years to support its Phase 3 study evaluating SGX942.
read more
Thursday, September 14, 2017
AgeneBio has been awarded a grant for up to $10 million from the National Institute on Aging of the National Institutes of Health to support its novel...
read more
Wednesday, September 13, 2017
Neuraltus and the John A. Burns School of Medicine announced Phase 1b placebo-controlled biomarker study of NP001 in individuals with Alzheimer's ...
read more
Monday, September 11, 2017
Bayer and Vanderbilt University Medical Center have agreed on a five-year strategic research alliance in the fight against kidney diseases.
read more
Friday, September 08, 2017
Regeneron and Sanofi announced the FDA has granted Breakthrough Therapy designation status to cemiplimab for metastatic CSCC and adults with locally ...
read more
Tuesday, September 05, 2017
Cellect Biotechnology announced the FDA has granted orphan drug designation for Cellect's ApoGraft for the prevention of acute and chronic GvHD in ...
read more
Friday, September 01, 2017
Heptares announced the first healthy subject has been dosed with the first-in-class, selective muscarinic M4 receptor agonist HTL0016878 in a Phase 1 ...
read more
Thursday, August 31, 2017
Daiichi Sankyo announced positive top-line results from the REDUCER study in patients with diabetic peripheral neuropathic pain, followed by a 52-week...
read more
Thursday, August 31, 2017
The FDA approved a personalized cellular therapy developed by the CHOP for the treatment of patients up to 25 years of age with B-cell precursor ALL ...
read more
AstraZeneca Pharmaceuticals
AstraZeneca and Takeda have entered an agreement to jointly develop and commercialize MEDI1341, an alpha-synuclein antibody currently in development ...
read more
Daiichi Sankyo announced the FDA has granted Breakthrough Therapy designation to DS-8201.
read more
Sangamo and Pfizer announced the first patient received treatment in the Phase 1/2 clinical trial evaluating SB-525, an investigational gene therapy ...
read more